189 related articles for article (PubMed ID: 26143067)
1. Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study.
Sgouros J; Aravantinos G; Kouvatseas G; Rapti A; Stamoulis G; Bisvikis A; Res H; Samantas E
J Gastrointest Cancer; 2015 Dec; 46(4):343-9. PubMed ID: 26143067
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
3. Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study.
Barth DA; Riedl JM; Posch F; Smolle MA; Kasparek AK; Niedrist T; Szkandera J; Stöger H; Pichler M; Stotz M; Gerger A
Clin Transl Oncol; 2019 Aug; 21(8):1034-1043. PubMed ID: 30671731
[TBL] [Abstract][Full Text] [Related]
4. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer.
Lohrisch C; Paltiel C; Gelmon K; Speers C; Taylor S; Barnett J; Olivotto IA
J Clin Oncol; 2006 Oct; 24(30):4888-94. PubMed ID: 17015884
[TBL] [Abstract][Full Text] [Related]
5. Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.
Stocker G; Hacker UT; Fiteni F; John Mahachie J; Roth AD; Van Cutsem E; Peeters M; Lordick F; Mauer M
Eur J Cancer; 2018 Aug; 99():49-57. PubMed ID: 29906734
[TBL] [Abstract][Full Text] [Related]
6. HER2 as a potential biomarker guiding adjuvant chemotherapy in stage II colorectal cancer.
Feng Y; Li Y; Huang D; Cai S; Peng J
Eur J Surg Oncol; 2019 Feb; 45(2):167-173. PubMed ID: 30420187
[TBL] [Abstract][Full Text] [Related]
7. Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy.
van Erning FN; Janssen-Heijnen ML; Creemers GJ; Pruijt JF; Maas HA; Lemmens VE
Int J Cancer; 2017 Jan; 140(1):224-233. PubMed ID: 27615021
[TBL] [Abstract][Full Text] [Related]
8. [Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
You KY; Peng HH; Gao YH; Chen L; Zhou GQ; Chang H; Du XJ; Xiao L; Zeng ZF; Wen BX; Liu MZ
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):708-13. PubMed ID: 24332061
[TBL] [Abstract][Full Text] [Related]
9. The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer.
Kim SG; Hwang SH
World J Surg Oncol; 2016 Apr; 14():102. PubMed ID: 27039375
[TBL] [Abstract][Full Text] [Related]
10. Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer.
Park HS; Jung M; Shin SJ; Heo SJ; Kim CG; Lee MG; Beom SH; Lee CY; Lee JG; Kim DJ; Ahn JB
Ann Surg Oncol; 2016 Mar; 23(3):928-35. PubMed ID: 26514121
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of interhospital variation in adjuvant chemotherapy for patients with Stage II/III colorectal cancer: a nationwide study.
Arakawa K; Kawai K; Tanaka T; Hata K; Sugihara K; Nozawa H
Colorectal Dis; 2018 Jul; 20(7):O162-O172. PubMed ID: 29752849
[TBL] [Abstract][Full Text] [Related]
12. Distinctive oncological features of stage IIIA colorectal cancer: Analysis of prognostic factors for selective adjuvant chemotherapy.
Park SY; Choi GS; Park JS; Kim HJ; Sakai Y; Hasegawa S; Watanabe T; Kim SH
J Surg Oncol; 2015 Jun; 111(7):882-90. PubMed ID: 25847023
[TBL] [Abstract][Full Text] [Related]
13. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
14. Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer.
Matsuoka H; Ando K; Hu Q; Zaitsu Y; Tsuda Y; Hisamatsu Y; Nakashima Y; Kimura Y; Oki E; Mori M
Int J Clin Oncol; 2020 Jul; 25(7):1318-1326. PubMed ID: 32279124
[TBL] [Abstract][Full Text] [Related]
15. The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.
Sunaga T; Suzuki S; Kogo M; Kurihara T; Kaji S; Koike N; Harada N; Suzuki M; Kiuchi Y
Eur J Cancer Care (Engl); 2014 May; 23(3):394-400. PubMed ID: 24033646
[TBL] [Abstract][Full Text] [Related]
16. Real-world Data for High-risk Stage II Colorectal Cancer - The Role of Tumor Side in the Adjuvant Setting.
Araujo CS; Venchiarutti Moniz CM; Bonadio RC; Watarai GY; Rojas J; Nogueira PVS; Martinez JK; Moraes PMG; Braghiroli MI; Sabbaga J; Hoff PM
Clin Colorectal Cancer; 2021 Jun; 20(2):e100-e108. PubMed ID: 33234431
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
Kim HR; Min BS; Kim JS; Shin SJ; Ahn JB; Rho JK; Kim NK; Rha SY
Oncology; 2011; 81(3-4):175-83. PubMed ID: 22057187
[TBL] [Abstract][Full Text] [Related]
18. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
Gal R; Sadikov E; Sulkes J; Klein B; Koren R
Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
Goéré D; Benhaim L; Bonnet S; Malka D; Faron M; Elias D; Lefèvre JH; Deschamps F; Dromain C; Boige V; Dumont F; De Baere T; Ducreux M
Ann Surg; 2013 Jan; 257(1):114-20. PubMed ID: 23235397
[TBL] [Abstract][Full Text] [Related]
20. Indication and efficacy of adjuvant chemotherapy with oral fluoropyrimidines for dukes' B colorectal cancer.
Yoshimatsu K; Umehara A; Ishibashi K; Yokomizo H; Yoshida K; Fujimoto T; Watanabe K; Ogawa K
Anticancer Res; 2006; 26(4B):3089-93. PubMed ID: 16886639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
